



26th February 2021

Dear Honourable Minister of Health,

Last week, we released a letter that the AstraZeneca AZD1222 vaccine has been granted Emergency Use Listing by WHO, and is thus authorised for delivery under the COVAX Facility. Following up on the 29th January letter regarding your indicative allocation, we are now pleased to share with you the final allocation for the first round of AZD1222 vaccine doses to be provided to your economy in the coming months.

This letter constitutes a binding notification of your Participant Doses pursuant to Clause 4.1 of the Commitment Agreement entered into between Brazil and Gavi (the “Commitment Agreement”). Terms defined in the Commitment Agreement have the same meaning when used in this letter unless otherwise defined. We are pleased to share the below information and instructions.

AstraZeneca

Brazil is allocated 9,122,400 doses of the AZD1222 vaccine through May 2021.

The Actual Procurement Price (and for Participants subscribed to the Committed Purchase Arrangement, the Adjusted Cost Per Dose) for this allocation is \$4 per dose, therefore the total purchase value owed by the participant is \$36,489,600. Please refer to the final cost estimate and purchase orders as communicated by the respective procurement agencies or manufacturer. For more information regarding allocation, we invite you to consult the key details in Annex A attached to this letter.

Pfizer/BioNTech

For participants who expressed interest in BNT162b2 Q2 doses, given the specificity of the vaccine and the additional requirements placed on countries by the manufacturer in order to access the vaccine, projected Q2 doses from Pfizer will be included through a separate allocation round in March. Based on early learnings from the first wave countries, the COVAX Facility will soon reach out with more information regarding Q2 doses.

For Optional Purchase Arrangement Participants that did not send a Non-Exercise Notice in respect of Pfizer doses, your Pro-Rata Share of Pfizer doses, which was shared at the opening of Window 2 on 22nd January 2021, are unaffected by this delay. The allocation of these doses will be communicated as soon as possible.

Procurement of AstraZeneca and next steps

This allocation allows for the procurement process to be set in motion for phased deliveries. As a reminder, the process for accessing allocated doses differs according to Participant type as described below. For more information, we invite you to consult the key details in Annex A attached to this letter.

- **All participants:**
 - Participants are required to have signed an indemnity agreement with AstraZeneca,
 - Participants are required to have executed and provided documentation of national regulatory approval or proof of recognition or reliance on another type of regulatory approval and if applicable communicated it to your respective procurement agency (PAHO Revolving Fund for the Region of Americas and UNICEF Supply Division for all other regions),

- Participants are required to have secured an import license provision for relevant vaccine products and if applicable communicated it to your respective procurement agency (PAHO Revolving Fund for the Region of Americas and UNICEF Supply Division for all other regions)
- **Self-financing participants procuring through UNICEF SD or PAHO RF:**
 - Ensure a Memorandum of Understanding is in place between the Participant and UNICEF SD if the Participant country is outside the Region of Americas.
 - Participants will receive a cost estimate from their procurement agency, as per standard process. The cost estimate will include all costs (including Actual Procurement Price, insurance, international transport costs and procurement fee) as well as delivery dates and incoterms. Participants are required to provide funds to UNICEF SD or PAHO RF in order for the procurement agent to place purchase orders on the Participant's behalf.
 - Participants are required to provide a signed Commitment Satisfaction Certificate in accordance with Clause 4.1 of the Commitment Agreement (see attached), which confirms the placement of a binding purchase order, to Gavi for its records (covax@gavi.org)
- **Self-financing participants that are self-procuring:**
 - Participants are required to enter into a supply agreement with the manufacturer and place a purchase order. [Note that the supply agreement is equivalent to the framework agreement between the Participant and manufacturer. The purchase is the specific order for a certain number of doses. Therefore, on subsequent allocations to Participant from the same manufacturer, only a purchase order will be required.]
 - Arrangements should be made for the international transport of the vaccine based on the INCOTERM. For reference guidance on International Transport of Vaccines, [see here](#).
 - Participants are required to provide a signed Commitment Satisfaction Certificate in accordance with Clause 4.1 of the Commitment Agreement (see attached), which confirms the placement of a binding purchase order, to Gavi for its records (covax@gavi.org)
 - Participants are required to inform the COVAX Procurement Coordinator of the date when the Purchase Order is placed, as well as the estimated and actual delivery date and quantity delivered. We request a copy of the countersigned Purchase Order and notice of vaccine arrival be sent to the attention of procurement_coordinator@unicef.org. This will ensure allocated doses are appropriately accounted for against the drawdown of COVAX Facility doses.

Please note that the above obligations (other than the Commitment Satisfaction Certificate and the reporting requirement on actual delivery date and quantity) must be fulfilled and evidence of such fulfilment provided to Gavi by 9th April, 2021 in order for you to comply with your obligations under Clause 4.1 of the Commitment Agreement. After this date Gavi may take action to address non-compliance with the Commitment Agreement which may include, without limitation, reallocating doses to other Participants. If a Participant anticipates that meeting this deadline will be challenging, please inform your Gavi focal point as soon as possible.

The Commitment Satisfaction Certificate which must be signed by you and the relevant manufacturer or procurement agent must be provided within 10 Business Days of having satisfied your obligation to purchase your Assigned Doses.

Please note that due to the high number of Participants covered under this allocation round, the capacity of the supplier and the freight forwarders will be under considerable pressure. When planning for the receipt of the

vaccines and program implementation, in addition to the preparedness requirements above, please also factor in supply lead time for (1) purchase order processing and approval, (2) final supply packing and release, (3) logistical preparedness and planning, and (4) shipping prioritization and lead times (which vary based on airline capacity availability, location of the participant, etc.).

Thank you for your continued engagement with the Facility. Please note that in order to maintain the COVAX Facility's commitment to transparency, we may publish on our website information related to participant status of pre-requisites, in order to provide clarity on the likely earliest deliveries for the first round of allocation. Following this letter, we will also make this allocation information publicly available soon after the weekend. If you require any further clarifications, do not hesitate to contact your focal point.

Sincerely,



Aurélia Nguyen
Managing Director
Office of the COVAX Facility